Clinical trials and soft tissue sarcomas

Surgical Oncology Clinics of North America

Volumn 12, Issue 2, 2003, Pages 485-497

  Rajput, Ashwani ^a,b   Kraybill, William G ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; IMATINIB; VINCRISTINE;

BONE MARROW SUPPRESSION; CANADA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHONDROSARCOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEMALE; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; OSTEOSARCOMA; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL CANCER; REVIEW; SOFT TISSUE SARCOMA; SURGICAL APPROACH; UNITED STATES;

EID: 0038752737     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(03)00002-4     Document Type: Review

References (34)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52: 23-47.
2. Cantin J, McNeer GP, Chu FC, et al. The problem of local recurrence after treatment of soft tissue sarcoma. Ann Surg 1968;168:47-53.
3. Gerner RE, Moore GE, Pickren JW. Soft tissue sarcomas. Ann Surg 1975;181:803-8.
4. Rosenberg SA, Glatstein EJ. Perspectives on the role of surgery and radiation therapy in the treatment of soft tissue sarcomas of the extremities. Semin Oncol 1981;8:190-200.
5. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-15.
6. Potter DA, Kinsella T, Glatstein E, et al. High-grade soft tissue sarcomas of the extremities. Cancer 1986;58:190-205.
7. Abbatucci JS, Boulier N, de Ranieri J, et al. Radiotherapy as an integrated part of the treatment of soft tissue sarcomas. Radiother Oncol 1984;2:115-21.
8. Leibel SA, Tranbaugh RF, Wara WM, et al. Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer 1982;50:1076-83.
9. Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft tissue sarcomas. Cancer 1981;47:2391-7.
10. Suit HD, Proppe KH, Mankin HJ, et al. Preoperative radiation therapy for sarcoma of soft tissue. Cancer 1981;47:2269-74.
11. National Institutes of Health. NIH consensus development panel on limb-sparing treatment of adult soft tissue sarcoma and osteosarcomas. Cancer Treat Symp 1985;3:1-5.
12. Pisters PWT, Harrison LB, Leung DHY, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14:859-68.
13. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.
14. McCarter MD, Jaques DP, Brennan MF. Randomized clinical trials in soft tissue sarcoma. Surg Oncol Clin North Am 2002;11:11-23.
15. Rosenberg SA, Tepper J, Glatstein E, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983; 52:424-34.
16. Chang AE, Kinsella T, Glatstein E, et al. Adjuvant chemotherapy for patients with high-grade soft tissue sarcomas of the extremity. J Clin Oncol 1988;6:1491-500.
17. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-85.
18. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma group. J Clin Oncol 1994;12:1137-49.
19. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma group. J Clin Oncol 1995;13:1537-45.
20. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-47.
21. Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol 2001;19:1235-7.
22. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 1997;350:1647-54.
23. Glenn J, Sindelar WR, Kinsella T, et al. Results of multimodality therapy of respectable soft tissue sarcomas of the retroperitoneum. Surgery 1985;97:316-25.
24. Eilber F, Eckardt J, Rosen G, et al. Preoperative therapy for soft tissue sarcomas. Hematol Oncol Clin North Am 1995;9:817-23.
25. Henshaw RM, Priebat DA, Perry DJ, et al. Survival after induction chemotherapy and surgical resection or high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol 2001;8:484-95.
26. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6.
27. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the multi -institutional osteosarcoma study. Clin Orthop 1991;270:8-14.
28. Brennan MF. More is less: systemic treatment for local control in soft tissue sarcoma. Ann Surg Oncol 2001;8:480-1.
29. Kraybill W, Spiro I, Harris J, et al. Radiation Therapy Oncology Group (RTOG) 95-14: a phase 11 study of neoadjuvant chemotherapy (CT) and radiation therapy (RT) in high risk (HR), high grade, soft tissue sarcomas (STS) of the extremities and body wall: a preliminary report [abstract]. Proc Am Soc Clin Oncol 2001;29:348a.
30. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD 34. Mod Pathol 1998; 11:728-34.
31. Druker BJ, Moshe T, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
32. Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117) [abstract 1]. Proc Am Soc Clin Oncol 2001;20:1a.
33. Van Oosterom AT, Judson I, Verweij J, et al. STI571, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC phase I study [abstract 2]. Proc Am Soc Clin Oncol 2001;;20:1a.
34. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1042-6.